AGEN earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E 3.20. Updated 2026-07-23.
Agenus (AGEN) Research Hub
Agenus (AGEN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 6.94 USD (+1.17%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 3.20, market cap 0.24B. This hub links to the full technical, earnings and options research available for AGEN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.94 USD (+1.17%) |
| 52-week range | 2.86 USD – 8.85 USD |
| Trend regime | Range |
| 14-day RSI | 49.8 (Neutral) |
| Trailing P/E | 3.20 |
| Market cap | 0.24B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for AGEN
Covered Call on AGEN: how it works, illustrative setup around the real 6.94 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AGEN: how it works, illustrative setup around the real 6.94 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AGEN: how it works, illustrative setup around the real 6.94 USD price, max profit/loss, breakeven and when to use it. Educational.
AGEN technical analysis: range, last 6.94 USD, RSI 49.8, 52w range 2.86 USD–8.85 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AGEN in?
Agenus (AGEN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AGEN in an uptrend or downtrend?
As of 2026-09-11, AGEN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AGEN's trailing P/E ratio?
AGEN's trailing P/E is 3.20, with a market cap of 0.24B. See the earnings research page for full valuation detail.
When does AGEN next report earnings?
AGEN is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of 0.05 USD.